Overall, while inflammation is a consistent feature of HD pathology, conflicting findings highlight the need for well-designed longitudinal studies with stratified patient cohorts to validate the clinical use of inflammatory biomarkers like IL-6, YKL-40, and IL-17 in HD diagnosis. The gene discussed is IL17A; the disease is Huntington disease.